Fig. 5.

Decreased WAY-161503 induced cFOS induction in the ARC of PWS-IC mice. a−d Immunohistochemical detection of cFOS immunoreactivity (denoted by black nuclear staining) within the ARC (Bregma −1.46) following administration of (a, b) vehicle and (c, d) 3 mg/kg WAY-161503 to WT and PWS-IC mice. e, f Quantification of cFOS induction at two distinct neuroanatomical levels of ARC (−1.46 and −1.70 mm from bregma) and across the nucleus as a whole in (e) WT and (F) PWS-IC mice following WAY-161503 administration. PWS-IC mice exhibit attenuated ARC cFOS-IR upon WAY-161503 administration. Data presented as Mean ± SEM, with statistical comparison performed by Student’s t-test, *p < 0.05, **p < 0.01 compared to vehicle controls. Scale bar in (A), 100 μm and relates to all images. 3 V, third ventricle